PCM
ORMP icon

Prelude Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Prelude Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Sell
32,713
-2,600
-7% -$10.3K 0.01% 1031
2026
Q1 		$120K Buy
35,313
+13,700
+63% +$46.5K 0.01% 1016
2025
Q4 		$61.6K Buy
+21,613
New +$55.7K ﹤0.01% 1226
2025
Q2 		– Sell
-13,435
Closed -$28.8K – 1261
2025
Q1 		$28.8K Sell
13,435
-300
-2% -$692 ﹤0.01% 1120
2024
Q4 		$33.2K Sell
13,735
-700
-5% -$1.66K ﹤0.01% 1163
2024
Q3 		$35.2K Buy
+14,435
New +$35.2K ﹤0.01% 1227

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prelude Capital Management's ORMP Position: Q2 2026 in Review

Prelude Capital Management reduced its Oramed Pharmaceuticals (ORMP) stake by 7.4% in Q2 2026, selling an estimated $10.3K and leaving 32,713 shares worth $157K. The position accounts for 0.01% of the portfolio, ranked #1031.

Prelude Capital Management first reported a position in ORMP in Q3 2024 and has held it in 6 quarters since. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Prelude Capital Management held 32,713 shares of Oramed Pharmaceuticals worth $157K as of Q2 2026.
  • Prelude Capital Management sold 2,600 Oramed Pharmaceuticals shares in Q2 2026, an estimated $10.3K.
  • Oramed Pharmaceuticals made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1031 holding.
  • Prelude Capital Management first reported a position in Oramed Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.